Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 21;10(5):817.
doi: 10.3390/vaccines10050817.

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

Daniele Lapa  1 , Daria M Grousova  2 , Giulia Matusali  1 , Silvia Meschi  1 , Francesca Colavita  1 , Aurora Bettini  1 , Giulia Gramigna  1 , Massimo Francalancia  1 , Anna Rosa Garbuglia  1 , Enrico Girardi  1 , Vincenzo Puro  1 , Andrea Antinori  1 , Anna V Kovyrshina  2 , Inna V Dolzhikova  2 , Dmitry V Shcheblyakov  2 , Amir I Tukhvatulin  2 , Olga V Zubkova  2 , Vladimir A Gushchin  2 , Denis Y Logunov  2 , Boris S Naroditsky  2 , Francesco Vaia  1 , Alexander L Gintsburg  2   3
Affiliations

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

Daniele Lapa et al. Vaccines (Basel). .

Abstract

The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. Omicron has become the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccines. Studies on the neutralizing activity of vaccinated sera against the Omicron variant are currently being carried out in many laboratories. In this study, we have shown the neutralizing activity of sera against the SARS-CoV-2 Omicron variant compared to the reference Wuhan D614G variant in individuals vaccinated with two doses of Sputnik V up to 6 months after vaccination and in individuals who experienced SARS-CoV-2 infection either before or after vaccination. As a control to our study we also measured neutralizing antibody titers in individuals vaccinated with two doses of BNT162b2. The decrease in NtAb titers to the Omicron variant was 8.1-fold for the group of Sputnik V-vaccinated individuals. When the samples were stratified for the time period after vaccination, a 7.6-fold or 8.8-fold decrease in NtAb titers was noticed after up to 3 and 3-to-6 months after vaccination. We observed a 6.7- and 5-fold decrease in Sputnik V-vaccinated individuals experiencing asymptomatic or symptomatic infection, respectively. These results highlight the observation that the decrease in NtAb to the SARS-CoV-2 Omicron variant compared to the Wuhan variant occurs for different COVID-19 vaccines in use, with some showing no neutralization at all, confirming the necessity of a third booster vaccination.

Keywords: Omicron; SARS-CoV-2; antibody response; neutralization; vaccine.

PubMed Disclaimer

Conflict of interest statement

GDM, DIV, SDV, TAI, ZOV, LDY, NBS and GAL report patents for a Sputnik V immunobiological expression vector, pharmaceutical agent and its method of use to prevent COVID-19. LD, MG, MS, CF, BA, GG, FM, GAR, PV and VF, declare no conflict of interest. AA declares no conflict of interest for the present work, and, outside of the present work, declares honoraria for consultancy, lectures or research grants from Gilead, Merck, Astra Zeneca, Roche, ViiV, GSK, Janssen, Mylan, Theratecnologies. EG declares no conflict of interest for the present work, and, outside of the present work, declares honoraria for consultancy, lectures or research grants from Gilead, ViiV, Mylan.

Figures

Figure 1
Figure 1
(A)—RBD-specific IgG titers in vaccinated individuals, median and 95% CI; (B)—NtAb titers against SARS-CoV-2 B.1 in vaccinated individuals, geometric mean titer and 95% CI, C, D—NtAb titers against SARS-CoV-2 B.1 (Wuhan D614G) and B.1.1.529 (Omicron) variants in Sputnik V- (C) and BNT162b2 (D)-vaccinated individuals, geometric mean titer and 95% CI, %—part of sera with detectable NtAb. p-value was determined by Wilcoxon test. Grey box—limit of detection. Values below the limit of detection were assigned a value of NtAb 1.25.
Figure 2
Figure 2
Titers of neutralizing antibodies in samples of individuals vaccinated with Sputnik V; vaccinated with Sputnik V after/before asymptomatic COVID-19; vaccinated with Sputnik V after/before mild COVID-19 and COVID-19 convalescents. The figure shows individual data for the studied samples, geometric mean and 95% CI. The figure shows the p-value (Wilcoxon test), % of individuals with detectable NtAb to the SARS-CoV-2, geometric mean and the level of NtAb decrease. Grey box—limit of detection. Values below the limit of detection were assigned a value of NtAb 1.25.
See this image and copyright information in PMC

References

    1. NewsNodes Omicron Variant Tracker. 2022. [(accessed on 14 April 2022)]. Available online: https://newsnodes.com/omicron_tracker/
    1. GISAID hCov19 Variants. 2022. [(accessed on 14 April 2022)]. Available online: https://www.gisaid.org/hcov19-variants/
    1. Edara V.V., Manning K.E., Ellis M., Lai L., Moore K.M., Foster S.L., Floyd K., Davis-Gardner M.E., Mantus G., Nyhoff L.E., et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. Cell Rep. Med. 2022;3:100529. doi: 10.1016/j.xcrm.2022.100529. - DOI - PMC - PubMed
    1. Muik A., Lui B.G., Wallisch A.K., Bacher M., Mühl J., Reinholz J., Ozhelvaci O., Beckmann N., Güimil Garcia R.C., Poran A., et al. Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2022;375:678–680. doi: 10.1126/science.abn7591. - DOI - PMC - PubMed
    1. Dejnirattisai W., Shaw R.H., Supasa P., Liu C., Stuart A.S., Pollard A.J., Liu X., Lambe T., Crook D., Stuart D.I., et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 2021;339:234–236. doi: 10.1016/S0140-6736(21)02844-0. - DOI - PMC - PubMed